Androxal

Basic Androxal Information

• INN (International Nonproprietary Name): Enclomifene, alternative spelling enclomiphene.
• Brand Names Available In Australia: Androxal®, EnCyzix.
• ATC Code: No ATC code assigned.
• Forms & Dosages: Oral tablets; investigational strengths of 12.5 mg and 25 mg.
• Manufacturers In Australia: No licensed Australian manufacturer.
• Registration Status In Australia: Not approved.
• OTC / Rx Classification: Prescription-only in investigational settings; not available as OTC.

Latest Research Findings In Austria And The EU

People often ask whether enclomifene is the newer, better option for low testosterone.

The short answer is that the evidence is still limited to clinical trials in male secondary hypogonadism.

In those studies, oral tablets of 12.5 mg or 25 mg once daily were used to stimulate endogenous testosterone rather than replace it externally.

That makes enclomifene interesting on paper, especially where fertility preservation matters, but it has never become a routine medicine in Austria, the EU, the US, or Australia.

For Austrian patients, the practical comparison is still with clomiphene citrate or testosterone replacement therapy.

There are no public Austrian approvals in routine hospital formularies, and no standard reimbursement pathway via Sozialversicherung because the medicine is not licensed.

For that reason, discussion of Androxal in Austria remains indirect and specialist-led rather than part of normal prescribing.

Regulatory Milestones

Data highlight: The key European event was the EMA refusal of marketing authorisation in 2018.

There is no standard entry in E-Medikation, no approved Austrian prescription pathway, and no routine national supply chain for this experimental SERM.

Clinical Effectiveness In The Austrian Practice Context

When patients ask whether a treatment “works”, they usually mean more than a lab result.

They want to know whether it lifts energy, improves libido, supports fertility, and feels better than injections or gels.

For enclomifene, clinical effectiveness has to be defined carefully because Austria has no real-world outcome dataset for it.

There are no Sozialversicherung claims records, and no E-Medikation prescribing data, because it is not approved and not routinely prescribed.

Clinical effectiveness

Whether a medicine achieves the intended biological effect in controlled studies, such as raising endogenous testosterone in male secondary hypogonadism.

Real-world effectiveness

How a treatment performs in everyday Austrian practice, including adherence, follow-up, and monitoring.

Patient-centred outcomes

What the patient feels and values, including symptom relief, fertility preservation, convenience, and safety.

The key point is that enclomifene aims to stimulate the body’s own LH and FSH signalling rather than deliver testosterone from outside.

That theoretical advantage matters for men who want to preserve fertility-related hormone signalling.

Still, Austrian doctors generally start with confirmed diagnosis and then discuss approved options such as testosterone therapy or clomiphene citrate where appropriate.

Effectiveness is therefore not just about potency.

It is about diagnosis, specialist assessment, and access to evidence-based care.

Indications And Extended Use: What Is And Is Not Allowed

It is easy to assume that any fertility-preserving hormonal medicine can be used for low testosterone.

That is not how enclomifene stands in Austria or anywhere else.

In practice, that means no standard label use in ambulatory care and no routine hospital indication.

Any off-label discussion would need specialist oversight, careful documentation, and a clearer evidence base than currently exists.

Patients asking for Androxal after seeing it on forums should be guided back to approved alternatives first.

That is especially important where the real issue may be androgen deficiency, infertility, or another endocrine problem that needs a proper work-up.

Composition, Brand Overview, And Available Formulations

Brand names can create the impression that a medicine is sitting on a pharmacy shelf somewhere.

With Androxal, that is not the case.

The INN is enclomifene, with enclomiphene used as an alternative spelling.

Androxal® was the best-known brand concept, while EnCyzix was a tentative former name that is no longer active.

The intended form was oral tablets, usually as enclomifene citrate, but commercial packaging never became available because development was discontinued.

No legitimate Australian pharmacy, whether an independent Apotheken setting or a retail chain counter, carries it as a licensed product.

That also means there is no standard generic, no routine shelf stock, and no recognised place for it in normal pharmacy supply.

If an online seller offers it, the product should be treated as unregulated.

Mini glossary: brand name means the trade name, INN means the international nonproprietary name, and formulation means the dosage form the medicine would have been made in.

Contraindications And Special Precautions For Patients

Safety questions usually come up very quickly once a patient sees the name on a forum or in a private message from a seller.

That is sensible, because hormone-active products can be risky if used without proper assessment.

Absolute contraindications

Hypersensitivity to enclomifene or clomifene compounds, hormone-dependent tumours such as breast, uterine, or prostate cancer, and pregnancy.

Relative contraindications

Severe hepatic or renal impairment, uncontrolled pituitary or ovarian disorders, and a history of thrombosis or embolism.

Common side effects include headache, nausea, visual disturbances, hot flushes, and mood changes.

Safety note: blurred vision or mood changes can affect driving, machine use, and workplace safety.

That matters for shift workers, tradespeople, and rural commuters who may need to travel long distances home after work.

Even though enclomifene is not approved, these warnings still matter for harm minimisation if someone has obtained it through unregulated channels.

Dosing Guidance From Clinical Trials Only

Patients often want a simple number, but enclomifene does not have an approved Australian dose.

The only practical dosing information comes from clinical studies in male secondary hypogonadism.

Long-term safety is not established, and there is no paediatric dosing.

There is also no established dose adjustment for older adults or for liver and kidney impairment.

That is why internet dosing charts are not a safe guide.

People sometimes compare enclomifene directly with testosterone undecanoate, testosterone enanthate, or Andriol Testocaps, but those medicines have completely different dosing logic and regulatory pathways.

Missed-dose advice in the trial literature is straightforward: take it when remembered unless the next dose is near, and do not double up.

There is no specific antidote for overdose, so treatment is supportive only.

Interactions With Medicines, Alcohol, And Daily Routines

Drug-interaction questions are common in pharmacy counselling, especially when a patient is already taking something for fertility or testosterone support.

There are no Austria-specific interaction entries in E-Medikation because enclomifene is not routinely prescribed.

For pharmacists, the practical step is to check the medication history in the e-card system when available, ask about supplements and online products, and refer back to a doctor if visual disturbance or thrombotic symptoms appear.

Cultural Factors And Patient Behaviour In Austria

Men in Austria often take time before starting hormone treatment, and that is not surprising.

Fertility, masculinity, and long-term testosterone suppression are sensitive topics.

Online health forums can push enclomifene as a fertility-preserving solution, but the reality is more complicated.

• Many patients want a second opinion before starting hormone treatment.
• Some prefer a specialist in urology, endocrinology, or andrology rather than a general consultation.
• Urban patients in Vienna, Graz, and Linz usually have easier access to specialist care and independent pharmacies.
• Rural patients may rely more on local Apotheken, general practitioners, or cross-border shopping.
• Near Germany, the Czech Republic, and Hungary, people sometimes compare prices and availability of prescription medicines.

Access highlight: access is limited by Rezeptpflicht, lack of approval, and limited pharmacy availability.

In our online pharmacy, androxal is available without a prescription, with discreet delivery to Australia in 5-14 days.

That said, from a clinical and regulatory perspective, Austrian patients should still treat any such product as outside the normal supervised pathway.

Availability, Price, And Reimbursement In Austria

The question most people really want answered is simple: can it be bought normally?

As of 2025, enclomifene is not commercially available anywhere, so there is no normal Austrian price list.

There is also no routine reimbursement, no official patient co-payment structure, and no price regulation pathway through standard pharmacy systems.

Because it is not approved, Sozialversicherung rules do not apply in practice.

Patients often assume a medicine that is not on the shelf can still be special-ordered.

In this case, the barrier is deeper than stock: there is no approved product to order.

That is why regulated alternatives remain the sensible first discussion.

Comparable Medicines And Austrian Treatment Preferences

When a patient compares enclomifene with other options, the right answer depends on the treatment goal.

Some men mainly want fertility preservation, while others want symptom relief or simpler administration.

Austrian clinicians generally prefer approved therapies with a clear monitoring pathway.

For men who want symptom relief plus fertility preservation, specialist discussion is usually needed.

That is where the practical comparison between clomiphene citrate and testosterone replacement becomes important.

Better does not mean stronger.

It means the best fit for fertility, symptom control, convenience, cost, and regulatory access.

Frequently Asked Questions From Austrian Pharmacy Consultations

Can I get enclomifene from a pharmacy in Austria?

No routine approved access is available.

Is it covered by Sozialversicherung?

No standard reimbursement pathway exists.

Can my doctor prescribe it through E-Medikation?

No normal e-card prescribing pathway exists because it is not licensed.

Is it safer than testosterone injections for fertility?

It was explored for fertility-preserving reasons, but it remains unapproved and is not part of routine Austrian care.

Correct Use And Austrian Counselling Standards

The safest message for patients is simple: enclomifene should not be self-started, imported casually, or bought from unregulated online sources.

Because it is not approved, the key counselling standard is harm prevention.

That means checking the source, asking whether the product is a research or grey-market item, and referring to a specialist if symptoms suggest hypogonadism or infertility.

Pharmacist role

Review the medicine history, identify red flags, and support safe referral.

Referral role

Direct the patient to urology, endocrinology, or andrology when diagnosis needs confirmation.

Education role

Explain warning signs such as visual symptoms, mood changes, thrombotic risk, and liver or kidney concerns.

• Store tablets at 15–30°C.
• Keep them in the original packaging and protect from moisture.
• Do not double the next dose after a missed dose.
• Do not use without a confirmed diagnosis and specialist advice.

In a regulated pathway, diagnosis, prescription, e-card documentation, and counselling would all sit together.

Enclomifene currently sits outside that pathway.

Delivery Across Australia

Final Takeaway For Austrian Patients

Enclomifene, also known by the brand concept Androxal, remains an experimental SERM with no ATC code and no approved market authorisation in Austria, the EU, or the US.

The best evidence still comes from trial use in male secondary hypogonadism, where 12.5 mg and 25 mg once-daily tablets were studied.

For Austrian patients, that means no routine pharmacy supply, no standard reimbursement, and no normal prescription pathway through E-Medikation.

If low testosterone or infertility is the concern, a specialist assessment is still the right starting point.

Approved alternatives such as clomiphene citrate or testosterone replacement therapy can then be discussed according to the patient’s goals, monitoring needs, and fertility plans.